Testing requirements, drug interactions hamper use of Pfizer COVID-19 antiviral pill - CP24 Toronto's Breaking News
4/19/2022 12:00:00 AM3 yearsago
by Michael Erman
by Michael Erman
Worldwide demand for Pfizer Inc's PFE.N oral COVID-19 antiviral treatment Paxlovid has been unexpectedly light due to complicated eligibility requirements, reduced testing, and potential for drug interactions, a Reuters review of data and interviews with expe…
April 19 (Reuters) -- Worldwide demand for Pfizer Inc's PFE.N oral COVID-19 antiviral treatment Paxlovid has been unexpectedly light due to complicated eligibility requirements, reduced testing, and … [+4980 chars]
full article...